Howe & Rusling’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.34M | Buy |
9,721
+203
| +2% | +$94.7K | 0.28% | 83 |
|
|
2025
Q4 | $4.31M | Buy |
9,518
+168
| +2% | +$72.4K | 0.29% | 83 |
|
|
2025
Q3 | $3.66M | Sell |
9,350
-94
| -1% | -$39.3K | 0.25% | 86 |
|
|
2025
Q2 | $4.2M | Buy |
9,444
+318
| +3% | +$147K | 0.31% | 81 |
|
|
2025
Q1 | $4.42M | Buy |
9,126
+232
| +3% | +$108K | 0.37% | 75 |
|
|
2024
Q4 | $3.58M | Sell |
8,894
-198
| -2% | -$91.8K | 0.31% | 76 |
|
|
2024
Q3 | $4.23M | Buy |
9,092
+315
| +4% | +$151K | 0.36% | 77 |
|
|
2024
Q2 | $4.11M | Buy |
8,777
+640
| +8% | +$278K | 0.38% | 77 |
|
|
2024
Q1 | $3.4M | Buy |
8,137
+101
| +1% | +$42.7K | 0.33% | 83 |
|
|
2023
Q4 | $3.27M | Buy |
8,036
+292
| +4% | +$108K | 0.35% | 77 |
|
|
2023
Q3 | $2.69M | Sell |
7,744
-267
| -3% | -$93.4K | 0.32% | 76 |
|
|
2023
Q2 | $2.82M | Sell |
8,011
-339
| -4% | -$114K | 0.32% | 74 |
|
|
2023
Q1 | $2.63M | Sell |
8,350
-218
| -3% | -$65.4K | 0.31% | 75 |
|
|
2022
Q4 | $2.47M | Sell |
8,568
-87
| -1% | -$26.5K | 0.31% | 72 |
|
|
2022
Q3 | $2.51M | Buy |
8,655
+306
| +4% | +$88K | 0.33% | 74 |
|
|
2022
Q2 | $2.35M | Buy |
8,349
+54
| +0.7% | +$14.5K | 0.3% | 78 |
|
|
2022
Q1 | $2.17M | Sell |
8,295
-2,994
| -27% | -$711K | 0.25% | 86 |
|
|
2021
Q4 | $2.48M | Sell |
11,289
-946
| -8% | -$184K | 0.29% | 80 |
|
|
2021
Q3 | $2.22M | Sell |
12,235
-452
| -4% | -$88.3K | 0.28% | 82 |
|
|
2021
Q2 | $2.56M | Buy |
12,687
+12,653
| +37,215% | +$2.65M | 0.32% | 77 |
|
|
2021
Q1 | $7K | Sell |
34
-6
| -15% | -$1.32K | ﹤0.01% | 556 |
|
|
2020
Q4 | $9K | Buy |
40
+11
| +38% | +$2.52K | ﹤0.01% | 507 |
|
|
2020
Q3 | $8K | Hold |
29
| – | – | ﹤0.01% | 486 |
|
|
2020
Q2 | $8K | Sell |
29
-9
| -24% | -$2.44K | ﹤0.01% | 465 |
|
|
2020
Q1 | $9K | Hold |
38
| – | – | ﹤0.01% | 440 |
|
|
2019
Q4 | $8K | Hold |
38
| – | – | ﹤0.01% | 496 |
|
|
2019
Q3 | $6K | Hold |
38
| – | – | ﹤0.01% | 535 |
|
|
2019
Q2 | $7K | Buy |
+38
| New | +$6.64K | ﹤0.01% | 498 |
|
|
2018
Q4 | – | Sell |
-30
| Closed | -$6K | – | 906 |
|
|
2018
Q3 | $6K | Buy |
+30
| New | +$5.34K | ﹤0.01% | 589 |
|
|
2018
Q2 | – | Sell |
-106
| Closed | -$17K | – | 947 |
|
|
2018
Q1 | $17K | Buy |
106
+62
| +141% | +$10.1K | ﹤0.01% | 417 |
|
|
2017
Q4 | $7K | Hold |
44
| – | – | ﹤0.01% | 515 |
|
|
2017
Q3 | $7K | Sell |
44
-18
| -29% | -$2.71K | ﹤0.01% | 536 |
|
|
2017
Q2 | $8K | Sell |
62
-23
| -27% | -$2.77K | ﹤0.01% | 536 |
|
|
2017
Q1 | $9K | Buy |
85
+5
| +6% | +$440 | ﹤0.01% | 541 |
|
|
2016
Q4 | $6K | Buy |
+80
| New | +$6.51K | ﹤0.01% | 639 |
|
|
2015
Q2 | – | Sell |
-5
| Closed | -$1K | – | 1114 |
|
|
2015
Q1 | $1K | Hold |
5
| – | – | ﹤0.01% | 891 |
|
|
2014
Q4 | $1K | Hold |
5
| – | – | ﹤0.01% | 870 |
|
|
2014
Q3 | $1K | Hold |
5
| – | – | ﹤0.01% | 855 |
|
|
2014
Q2 | $0 | Sell |
5
-247
| -98% | -$17.3K | ﹤0.01% | 929 |
|
|
2014
Q1 | $18K | Buy |
+252
| New | +$20K | ﹤0.01% | 474 |
|
|
2013
Q4 | – | Sell |
-247
| Closed | -$19K | – | 885 |
|
|
2013
Q3 | $19K | Hold |
247
| – | – | 0.01% | 482 |
|
|
2013
Q2 | $20K | Buy |
+247
| New | +$18.2K | 0.01% | 490 |
|
Other funds holding VRTX
VCM
VPM
Howe & Rusling's VRTX Position: Q1 2026 in Review
Howe & Rusling increased its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q1 2026, buying an estimated $94.7K and bringing the position to 9,721 shares worth $4.34M. The position accounts for 0.28% of the portfolio, ranked #83.
Howe & Rusling first reported a position in VRTX in Q2 2013 and has held it in 42 quarters since. The position peaked at $4.42M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Howe & Rusling held 9,721 shares of Vertex Pharmaceuticals worth $4.34M as of Q1 2026.
- Howe & Rusling bought 203 Vertex Pharmaceuticals shares in Q1 2026, an estimated $94.7K.
- Vertex Pharmaceuticals made up 0.28% of Howe & Rusling's portfolio in Q1 2026, its #83 holding.
- Howe & Rusling first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
- Howe & Rusling's Vertex Pharmaceuticals position peaked at $4.42M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Howe & Rusling's 13F filing for Q1 2026, filed 28 Apr 2026.